Prosecution Insights
Prosecution Insights
12 pending office actions • 8 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (50%) |
| No statute on record | 6 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HILL, KEVIN KAI | 1 | 36.2% | +33.4% |
| CHONG, KIMBERLY | 1 | 72.4% | +12.7% |
| GONZALES, JOSEPHINE MARIA | 1 | 29.8% | +42.1% |
| SPENCE, JENNIFER SUZANNE | 1 | 65.8% | +47.7% |
| DHAR, MATASHA | 1 | 44.7% | +50.1% |
| SINGH, ANOOP KUMAR | 1 | 42.8% | +67.6% |
| LEITH, NANCY J | 1 | 74.7% | +43.8% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 60.9% | +38.7% |
| GRABER, JAMES J | 1 | 46.2% | +56.1% |
| VYAS, KEYUR ANILKUMAR | 1 | 51.5% | +63.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 66d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | SULLIVAN, STEPHANIE LAUREN | 114d overdue |
| 17666390 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | DHAR, MATASHA | 92d overdue |
| 18059213 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | CHONG, KIMBERLY | 70d overdue |
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 66d overdue |
| 17430382 | MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY | GRABER, JAMES J | 56d overdue |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 53d overdue |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | HILL, KEVIN KAI | 30d overdue |
| 17757069 | MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | SPENCE, JENNIFER SUZANNE | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1631 | 2 |
| 1632 | 2 |
| 1635 | 2 |
| 1638 | 1 |
| 1633 | 1 |
| 1637 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | HILL, KEVIN KAI | 1638 | Other | Non-Final OA | 30d overdue | Pending | Dec 12, 2023 |
| 18059213 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | CHONG, KIMBERLY | 1636 | §103 | Non-Final OA | 70d overdue | Pending | Nov 28, 2022 |
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Non-Final OA | 66d overdue | Pending | Jun 17, 2022 |
| 17757069 | MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | SPENCE, JENNIFER SUZANNE | 1633 | Other | Final Rejection | 30d overdue | Pending | Jun 08, 2022 |
| 17666390 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | DHAR, MATASHA | 1632 | Other | Non-Final OA | 92d overdue | Pending | Feb 07, 2022 |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 1632 | §103 | Final Rejection | 53d overdue | Pending | Jan 10, 2022 |
| 17533007 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | LEITH, NANCY J | 1636 | §103 | Final Rejection | 28d | Pending | Nov 22, 2021 |
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | SULLIVAN, STEPHANIE LAUREN | 1635 | Other | Non-Final OA | 114d overdue | Pending | Aug 25, 2021 |
| 17430382 | MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY | GRABER, JAMES J | 1631 | Other | Non-Final OA | 56d overdue | Pending | Aug 12, 2021 |
| 16474198 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | VYAS, KEYUR ANILKUMAR | 1637 | Other | Final Rejection | 8d | Pending | Jun 27, 2019 |
| 16098464 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | TINSLEY, BRENDAN THOMAS | 1634 | §103 | Final Rejection | 98d overdue | Pending | Nov 02, 2018 |
| 16093334 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 1635 | §103 | Final Rejection | 40d | Pending | Oct 12, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial